RecruitingPhase 1Phase 2NCT05451602

HEC169096 in Participants With Advanced Solid Tumors

Phase 1/2 Study of the Highly-selective RET Inhibitor,HEC169096 in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors

Sponsor

Sunshine Lake Pharma Co., Ltd.

Enrollment

456 participants

Start Date

Oct 21, 2022

Study Type

INTERVENTIONAL

Conditions

Advanced Solid Tumor

Summary

An Open, Multi-Center Phase I/II Clinical Study To Evaluate The Safety, Tolerability, Pharmacokinetic Characteristics And Effectiveness Of HEC169096 In Patients With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study tests a new investigational drug called HEC169096 in people with advanced solid tumors (cancers that have not responded to standard treatments). This is an early-phase study to determine the safest dose, how the drug behaves in the body, and whether it shows any early signs of working against the cancer. **You may be eligible if...** - You have an advanced solid tumor that has progressed despite standard treatment options - You are 18 or older with adequate organ function (liver, kidneys, blood counts) - Your general health is good enough to participate (ECOG performance status 0–1) - You are able to provide informed consent **You may NOT be eligible if...** - You have untreated or unstable brain metastases - You have serious heart, liver, or kidney disease - You are pregnant or breastfeeding - You are receiving other cancer treatments that would interfere with the study drug - You have had recent major surgery or serious infection Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.